SARS-CoV-2 vaccination in IBD: more pros than cons

Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed...

Full description

Saved in:
Bibliographic Details
Published in:Nat Rev Gastroenterol Hepatol
Main Authors: D’Amico, Ferdinando, Rabaud, Christian, Peyrin-Biroulet, Laurent, Danese, Silvio
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2021
Subjects:
Comment
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7816748/
https://ncbi.nlm.nih.gov/pubmed/33473178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41575-021-00420-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items